Last $7.61 USD
Change Today 0.00 / 0.00%
Volume 1.1M
PDLI On Other Exchanges
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

pdl biopharma inc (PDLI) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $10.26
52 Week Low
10/7/14 - $7.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PDL BIOPHARMA INC (PDLI)

Related News

No related news articles were found.

pdl biopharma inc (PDLI) Related Businessweek News

No Related Businessweek News Found

pdl biopharma inc (PDLI) Details

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

10 Employees
Last Reported Date: 11/10/14
Founded in 1986

pdl biopharma inc (PDLI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.2M
Chief Financial Officer and Vice President
Total Annual Compensation: $323.2K
Vice President, General Counsel and Secretary
Total Annual Compensation: $659.7K
Chief Accounting Officer and Controller
Total Annual Compensation: $105.0K
Vice President of Business Development
Total Annual Compensation: $509.6K
Compensation as of Fiscal Year 2013.

pdl biopharma inc (PDLI) Key Developments

PDL BioPharma, Inc. Provides Revenue Guidance for the Fourth Quarter Ending December 31, 2014

PDL BioPharma, Inc. announced the revenue guidance for the fourth quarter ending December 31, 2014. For the quarter, the company's revenue expected to be of 158 million, as compared with actual of $112 million for the fourth quarter.

PDL BioPharma, Inc. Announces Amendments to its Bylaws

Effective as of December 4, 2014, the Board of Directors of PDL BioPharma, Inc. amended the company's Bylaws to improve corporate governance, clarify certain items in accordance with the General Corporation Law of Delaware and address recent Delaware case law and developments.

PDL BioPharma, Inc. Announces Regular Quarterly Dividend, Payable on December 12, 2014

PDL BioPharma, Inc. announced conversion rates for the notes are adjusted in connection with the regular quarterly dividend of $0.15 to be paid on December 12, 2014, to all stockholders who own shares of PDL on December 5, 2014, the record date.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDLI:US $7.61 USD 0.00

PDLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €7.50 EUR -0.06
BioInvent International AB kr2.73 SEK +0.20
Genmab A/S kr354.30 DKK -6.10
XOMA Corp $3.68 USD +0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation PDLI Industry Range
Price/Earnings 3.9x
Price/Sales 2.7x
Price/Book 3.1x
Price/Cash Flow 3.8x
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDL BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at